Search results :

Zoledronic acid

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: M05BA08

Side effects

Options: Hide MedDRA Preferred Terms ,   display all 40 labels

MedDRA Preferred Term Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Malignant neoplasm progression Neoplasm malignant aggravated 17% - 20% 20% x x x x x x x x x x
Anaemia Anaemia postmarketing — 4.4% - 22% 3.6% - 5.2% x x x x
Urinary tract infection Urinary tract infection 12% - 15% x x x x x x x x x x x x
Insomnia Insomnia 10% - 13% x x x x x x x x x x x x
Insomnia NEC x
Pain in extremity Pain in extremity 3.9% - 16% 4.8% - 9.9% x x x x x x x x x x x x x x
Confusional state Confusional state rare, 11% - 13% x x x x x x x x x x x x x x
Feeling abnormal Confusional state rare, 11% - 13% x x x x x x x x x x x x x x
Malaise postmarketing — 0.7% - 7.2% 0.5% - 1% x x x x x x x x x x x x x
Cough Cough uncommon, 10% - 12% x x x x x x x x x x x x x x x
Hypokalaemia Hypokalaemia uncommon, 10% - 16% x x x x x x x x x x x x x x
Agitation Agitation 8% - 11% x x x x x x x x x x x
Headache Headache postmarketing — 3.9% - 20.4% 2.5% - 11.4% x x x x x x x x x x x x x x x x x x x x
Anxiety Anxiety uncommon, 8% - 12% x x x x x x x x x x x x x x
Anxiety NEC x
Osteoarthritis Osteoarthritis 5.7% - 9.1% 4.5% - 9.7% x x
Candida infection Candida infection 4% - 12% x x x x x x x x x x x
Hypophosphataemia Hypophosphataemia common — 1% - 51% 0.2% - 3% x x x x x x x x x x x x x x
Hypertension Hypertension uncommon — 5.1% - 12.7% 5.4% - 12.4% x x x x x x
Influenza Influenza 5% - 7% x x x x x x
Constipation Constipation uncommon — 5% - 23% 6.9% x x x x x x x x x x x x x x x x x x x
Diarrhoea Diarrhoea postmarketing — 5.2% - 17% 4.7% - 7.9% x x x x x x x x x x x x x x x x x x x x
Nausea Nausea postmarketing — 4.5% - 28% 4.5% - 7.9% x x x x x x x x x x x x x x x x x x x x
Non-cardiac chest pain Non-cardiac chest pain 3.5% - 7.7% 3% x x
Back pain Back pain 1.7% - 18.2% 11.9% x x x x x x x x x x x x x x x x
Arthralgia Arthralgia postmarketing — 3% - 27.3% 18.3% - 20.4% x x x x x x x x x x x x x x x x x x x x
Musculoskeletal discomfort Arthralgia postmarketing — 3% - 27.3% 18.3% - 20.4% x x x x x x x x x x x x x x x x x x x x
Myalgia postmarketing — 4% - 22.7% 2.7% - 6.9% x x x x x x x x x x x x x x x x x x x x
Dyspnoea Dyspnoea uncommon — 1% - 20% x x x x x x x x x x x x x x x x x x x x
Oesophagitis Oesophagitis common x
Flushing Flushing common x x x x x
Nasopharyngitis Nasopharyngitis common x x
Pain Pain uncommon — 1.5% - 24.2% 0.5% - 3.5% x x x x x x x x x
Tachycardia Tachycardia common
Thirst Thirst common x
Blood urea increased Blood urea increased common x x
Bone pain Bone pain postmarketing — 3.2% - 12% 1% - 2.3% x x x x x x x x x x x x x x x x x x x x
Chills Rigors common, 1% - 8% x x x x x x x x x x x x x x x x x x
Chills postmarketing, 1.5% - 18.2% 0.5% - 3% x x x x x x x x x x x x x x
Musculoskeletal stiffness Stiffness common
Musculoskeletal stiffness 0% - 4.6% x x x x x
Musculoskeletal chest pain Musculoskeletal chest pain common x x
Renal failure Renal impairment postmarketing, common x
Renal failure x x x x x x x x x x x x x
Renal impairment Renal impairment postmarketing, common x
Neck pain Neck pain 1.4% - 6.6% 1.1% - 5% x x x
Breast cancer Breast cancer 4.3% x x x x x x x x x x x x
Advanced breast cancer postmarketing x x x x x x x x
Joint stiffness Joint stiffness common, 1.1% - 3.5% 2% x x x
Infection Infection postmarketing, 4% - 12% x x x x x x x x x x x x x x x x x x x
Dizziness Dizziness uncommon, 2% - 9% 3.5% - 6.7% x x x x x x x x x x x x x x x x x x x
Syncope uncommon x x x
Dyspepsia Dyspepsia uncommon — 1.7% - 7.1% 1.6% - 5% x x x x x x x x x x x x x x x x x
Musculoskeletal pain Shoulder pain 0% - 6.9% 0% - 5.6% x x x
Musculoskeletal pain postmarketing — 0.4% - 12.4% 0.3% - 7.9% x x x x x x x x x
Lethargy Lethargy common, 1% - 5% x x x x x x
Muscle spasms Muscle spasms 1.5% - 5.6% 1.7% - 5% x x x
Cramp muscle postmarketing, uncommon x x x x x x x x x x x
Neoplasm Neoplasm 3.2% x x
Prostate cancer Prostate cancer 3.1% x x
Oedema peripheral Oedema peripheral uncommon — 1% - 5.6% 3.5% - 5.3% x x x x x x x x x
Leg edema x x x x x x x x x x x
Edema of lower extremities x x x x x x x x x x
C-reactive protein increased C-reactive protein increased 1.4% - 4.6% x x
Pain in jaw Pain in jaw 2% - 3.9% 2.5% x
Hyperhidrosis Hyperhidrosis common, 2% - 2.6% x x x
Sweating increased postmarketing, uncommon x x x x x x x x x x
Atrial fibrillation Atrial fibrillation uncommon, 2% - 3.3% 1.9% - 2.6% x
Asthenia Fatigue postmarketing — 2.1% - 17.6% 1.2% - 4% x x x x x x x x x x x x x x x x x x x
Asthenia postmarketing — 1% - 6.1% 1% - 3% x x x x x x x x x x x x x x x x x x x x
Fatigue Fatigue postmarketing — 2.1% - 17.6% 1.2% - 4% x x x x x x x x x x x x x x x x x x x
Creatinine renal clearance decreased Creatinine renal clearance decreased 2% - 2.1% 1.7% - 2.4% x
Myalgia Myalgia postmarketing — 4% - 22.7% 2.7% - 6.9% x x x x x x x x x x x x x x x x x x x x
Abdominal pain Abdominal pain uncommon — 2% - 14% 7.9% x x x x x x x x x x x x x x x x x x x
Gastrointestinal pain Abdominal pain uncommon — 2% - 14% 7.9% x x x x x x x x x x x x x x x x x x x
Decreased appetite Anorexia common, 0.6% - 14% 0% - 1.1% x x x x x x x x x x x x x x x x x x x x
Decreased appetite x x x x x x x x x x x
Dermatitis Rash uncommon, 2% - 3% 2.5% x x x x x x x x x x x x x x x x x x x
Dermatitis x x x x x x x x x x
Rash Rash uncommon, 2% - 3% 2.5% x x x x x x x x x x x x x x x x x x x
Body temperature increased Body temperature increased postmarketing — 0.3% - 38% 0.1% - 4.6% x x x x x x x x x x x x x x x x x x x x
Hypotension Hypotension uncommon, 2% - 11% x x x x x x x x x x x x x x
Vomiting Vomiting postmarketing — 2% - 17% 3.2% - 4.5% x x x x x x x x x x x x x x x x x x x x
Vertigo Vertigo 1.3% - 4.3% 1% - 4% x x x x x x x x x x x x x
Abdominal discomfort Abdominal discomfort 1.1% - 2% 0.5% x
Abdominal distension Abdominal distension 0.6% - 2% 0% x x x x
Abdominal pain upper Abdominal pain upper 0.9% - 4.6% 1.5% - 3.1% x x x x x x
Blood creatinine increased Blood creatinine increased 0.7% - 2% x x x
Flank pain Flank pain 0.6% - 2% 0% x
Chest pain Chest pain uncommon, 1.3% - 2.4% 1.1% - 1.8% x x x x x x x x x x x x x x x
Palpitations Palpitations 0% - 2.6% x x
Hypermagnesaemia Hypermagnesaemia 1% - 2% 0.5% - 2% x x x x x x x x
Eye pain Eye pain 0% - 2% x x
Hypoaesthesia Hypoaesthesia uncommon, 2.2% - 5.6% 2% x x x x x x x x x x x x x x
Numbness very rare x x
Leukopenia Leukopenia uncommon x x x
Paraesthesia Paraesthesia uncommon — 0% - 2% x x x x x x x x x x x x x x x x x
Paraesthesia NEC x
Pruritus Pruritus uncommon x x x x x x x x x x x x x x x x x
Sleep disorder Sleep disturbance uncommon x x
Sleep disorder x
Stomatitis Stomatitis uncommon x x x x x x x x x x x
Swelling Swelling uncommon x x x x x x x x x x x x x x x x
Shock Syncope uncommon x x x
Shock postmarketing, uncommon x x x x x x x x x x x x x x x x
Syncope Syncope uncommon x x x
Loss of consciousness Syncope uncommon x x x
Thrombocytopenia Thrombocytopenia uncommon x x x x x x x x x x x x x x
Injection site reaction Injection site reaction uncommon x x x x x x x x x x x x x
Rash macular Rash macular uncommon x x x
Induration Induration uncommon x x x
Erythema Redness uncommon x x x x x x x x x x x x x x x
Erythema x
Somnolence Somnolence uncommon x x x x x x x x x x x x x x x
Hypocalcaemia Hypocalcaemia very rare — 1% - 3% 0.2% - 1% x x x x x x x x x x x x x x x x x x x x
Hypomagnesaemia Hypomagnesaemia uncommon, 1% - 9% 1% - 2% x x x x x x x x x x x x x x
Acute phase reaction Acute phase reaction postmarketing — 0% - 3.9% x x x x x x x x x x x x x x x x
Anaphylactic shock Anaphylactic shock postmarketing, uncommon x x x x x x x x x x x x x x x x
Angioedema Angioedema postmarketing, rare x x x x x x x x x x x x x x x x
Arthritis Arthritis postmarketing — 2.2% - 4% 1.5% x x x x x x
Coagulopathy Coagulopathy postmarketing x x x
Bronchospasm Bronchospasm postmarketing x x x x x x x x
Bronchoconstriction postmarketing, uncommon x x x x x x x x x x x x x x x x
Neoplasm malignant Neoplasm malignant postmarketing, 14% - 21% x x x x x x x x
Conjunctivitis Conjunctivitis postmarketing, common x x x x x x x x x x x x x x x x x x x
Dehydration Dehydration postmarketing, 0.6% - 2.5% 0.6% - 2.3% x x x x x x x x x x x x x x x x x
Dysgeusia Dysgeusia postmarketing, uncommon x x x x x x x x x x x
Oedema Oedema postmarketing x x x
Episcleritis Episcleritis very rare, postmarketing x x x x x x x x x x x x x x x x x
Femur fracture Femur fracture postmarketing x x x x x x x x x x
Haematuria Haematuria postmarketing, uncommon x x x x x x x x x x x
Hyperaesthesia Hyperaesthesia postmarketing, uncommon x x x x x x x x x x x
Hyperkalaemia Hyperkalaemia postmarketing, rare x x x x x x x x x x x
Hypernatraemia Hypernatraemia postmarketing, rare x x x x x x x x x x x
Hypersensitivity Hypersensitivity postmarketing, uncommon x x x x x x x x x x x x x x x x
Inflammation Inflammation postmarketing, uncommon x x x x x x x x x x x x x x x
Iridocyclitis Iridocyclitis postmarketing x x x
Iritis Iritis postmarketing x x x x x x x x x x x x x x
Renal failure acute Renal failure acute postmarketing, uncommon x x x x x x x x x
Oral disorder Oral disorder postmarketing x x
Plasma cell myeloma Plasma cell myeloma postmarketing, 3.2% x x x x x x x x x x
Plasmacytoma Plasma cell myeloma postmarketing, 3.2% x x x x x x x x x x
Osteonecrosis Osteonecrosis postmarketing x x x x x x x x x x x
Necrosis ischaemic x
Pancytopenia Pancytopenia rare x x x x x x x x x x x x x x
Proteinuria Proteinuria postmarketing, uncommon x x x x x x x x x x x x x
Protein urine present Proteinuria postmarketing, uncommon x x x x x x x x x x x x x
Scleritis Scleritis postmarketing, uncommon x x x x x x x x x x x x x x x
Tremor Tremor postmarketing, uncommon x x x x x x x x x x x x
Urticaria Urticaria postmarketing, uncommon x x x x x x x x
Uveitis Uveitis very rare — uncommon x x x x x x x x x x x x x x x x x
Weight increased Weight increased postmarketing, uncommon x x x x x x x x x x x
Dry mouth Dry mouth postmarketing, uncommon x x x x x x x x x x x x
Joint swelling Joint swelling postmarketing — 0.6% - 3% 0% x x x x x x
Interstitial lung disease Interstitial lung disease postmarketing, rare x x x x x x x x x x
Malaise Malaise postmarketing — 0.7% - 7.2% 0.5% - 1% x x x x x x x x x x x x x
Discomfort Malaise postmarketing — 0.7% - 7.2% 0.5% - 1% x x x x x x x x x x x x x
Ill-defined disorder Malaise postmarketing — 0.7% - 7.2% 0.5% - 1% x x x x x x x x x x x x x
Vision blurred Vision blurred postmarketing, uncommon x x x x x x x x x x x
Asthma Exacerbation of asthma postmarketing x x x
Influenza like illness Influenza-like symptoms postmarketing, 6.7% - 8% x x x x x
Influenza like illness postmarketing, 0.8% - 11% 0.4% - 2.7% x x x x x x x x x x x x x x x x
Orbital oedema Orbital oedema postmarketing x x x x x x x
Bradycardia Bradycardia rare x x x
Osteonecrosis of jaw Osteonecrosis of jaw postmarketing, uncommon x x x x x x x x x x x x x x x x x
Arrhythmia Arrhythmia very rare x x
Sensory loss Numbness very rare x x
Convulsion Convulsion very rare x x
Tetany Tetany very rare x x
Agranulocytosis Agranulocytosis x x x x x x x x x x x
Alopecia Alopecia x x x x x x x x x x
Atrial flutter Atrial flutter x
Mental disorder Mental disorder x x x x
Bone disorder Bone disorder x x x x x x
Connective tissue disorder Connective tissue disorder x x x x x
Dysphagia Dysphagia x x x x x x x x x x x
Depression Depression x x x x x x x x x x
Anxiety depression
Endophthalmitis Endophthalmitis x x
Ocular hyperaemia x
Panophthalmitis Endophthalmitis x x
Eye disorder Eye disorder x x x x x
Gastritis Gastritis x
Gastrooesophageal reflux disease Gastrooesophageal reflux disease x
Gastrointestinal disorder Gastrointestinal disorder x x x x x x x x x
Reaction gastrointestinal x x x x
Cardiac disorder Cardiac disorder x x x x x x
Hypogonadism Hypogonadism x
Immune system disorder Immune system disorder x x x x
Renal failure chronic Renal failure chronic x
Mediastinal disorder Mediastinal disorder x x x x x x x x x
Musculoskeletal disorder Musculoskeletal disorder
Necrosis ischaemic Necrosis ischaemic x
Metastasis Metastasis x x x
Nervous system disorder Nervous system disorder x x x x x x x x x
Neutropenia Neutropenia x x x x x x x x x x
Night sweats Night sweats
Osteomyelitis Osteomyelitis x x x
Osteopenia Osteopenia x
Pleural effusion Pleural effusion x x x
Toothache Toothache x
Upper respiratory tract infection Upper respiratory tract infection x x x x x x x x x x
Pollakiuria Pollakiuria x
Urethral disorder Urinary tract disorder x x x x x
Urinary tract disorder Urinary tract disorder x x x x x
Angiopathy Angiopathy x x x x
Weight decreased Weight decreased x x x x x x x x x x
Spinal fracture Spinal fracture
Cataract Cataract x
Electrolyte imbalance Electrolyte abnormality x x x
Blood electrolytes abnormal Electrolyte abnormality x x x
Muscular weakness Muscular weakness x
Ocular hyperaemia Ocular hyperaemia x
Malnutrition Malnutrition x x x x x x
Skin disorder Unspecified disorder of skin and subcutaneous tissue x x x x x x x x
Cardiac fibrillation Cardiac fibrillation x
Abdominal pain lower Abdominal pain lower x
Blood creatinine decreased Creatinine low x
Oropharyngeal discomfort Throat sore x x x x x x x x
Oropharyngeal pain Throat sore x x x x x x x x
Azotaemia Azotaemia x
Mucosal inflammation Mucosal inflammation x x x x x x x x x x x
Blood creatinine abnormal Serum creatinine abnormal x x x x x x x x x x x
Nephropathy toxic Nephropathy toxic x x x x x x x x x x
Renal cancer Renal cancer x x x x x x x x
Infestation Infestation NOS x x x x x x
Local reaction Local reaction x x x x x x x x x x x x x x x x
Infusion related reaction Infusion related reaction
Infusion site reaction Infusion site reaction x
Bone density decreased Bone mass decreased x
Atypical femur fracture Atypical femur fracture x x
Blood calcium decreased Blood calcium decreased x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

zoledronic acid / Zometa

Side effects:46
Source:FDA

ZOLEDRONIC ACID / RECLAST

Side effects:49
Source:FDA

ZOLEDRONIC ACID ANHYDROUS

Side effects:57
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:60
Source:FDA Structured Product Label

zoledronic acid / Zometa

Side effects:65
Source:FDA

zoledronic acid / Zometa

Side effects:68
Source:FDA

ZOLEDRONIC ACID / ACLASTA

Side effects:69
Source:Health Canada

Zoledronic Acid / Zometa, Powder for infusion

Side effects:98
Source:Medsafe

ZOLEDRONIC ACID / ZOMETA

Side effects:99
Source:FDA

ZOLEDRONIC ACID ANHYDROUS

Side effects:103
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:103
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:104
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:104
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:104
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:105
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:105
Source:FDA Structured Product Label

ZOLEDRONIC ACID ANHYDROUS

Side effects:106
Source:FDA Structured Product Label

zoledronic acid / zoledronic acid

Side effects:109
Source:EMA

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label